Early Access — free while we kick the tires
EdgarHawk

SMNR Semnur Pharmaceuticals, Inc. Insider Trading

Semnur Pharmaceuticals, Inc. (SMNR)'s reported leadership includes CEO Henry Ji Ph.D.. Its Form 4 history breaks down as 0 buys and 1 sell, filed by 1 distinct insider through Sep 2025.

1 filing analyzed · Latest 2025-09-25

Get alerts for SMNR

Free Form 4 email alerts, scored for significance — see how.

Buys
0
Sells
1
Insiders
1
Direction
Net selling

Semnur Pharmaceuticals, Inc. leadership

CEO
Henry Ji Ph.D. — PRINCIPAL EXECUTIVE OFFICER
CFO
Stephen Ma — PRINCIPAL FINANCIAL OFFICER
Chair
Ph.D. Henry Ji — Chief Executive Officer, President and Executive Chairperson

Historically, stocks have lagged the S&P 500 by a median ~4% over the 90 days after a high insider sell (n ≈ 3,996, 2024-2026). Past results don't predict the future. How we measure this ↗

September 2025
2025-09-25
high
12,500,000 shares
$200,000,000
@ $16.00
Significance 8

Scilex Holding Co sold 12,500,000 shares (96.2% reduction) at $16.00 for $200,000,000 in 2 separate transactions.

A 10% owner executed two separate sales totaling 12,500,000 shares for $200,000,000, reducing its stake from 13,000,000 shares to 500,000 shares—a 96.2% reduction in holdings. The transactions occurred at $16.00 per share while current price is $19.00, and this follows a very recent listing (2 trading days), meaning the company is newly public and traditional liquidity/performance history is not yet established. The company generated Revenue $50,000,000 in the latest quarter with a Net income of $-385,122 and posted zero annual revenue growth (FY vs prior FY), indicating unprofitability over the most recent full fiscal year. The near-complete exit by a controlling shareholder during the immediate post-IPO window—when shares priced at $16.00 but now trade at $19.00—warrants close examination of the founder's confidence in the business trajectory and capital allocation priorities.

Insiders here also file at

More Chemicals and Allied Products companies